Pfizer CFO Dave Denton To Step Down In August; Cecile Guegan Named Interim Successor

Dave Denton will step down as Chief Financial Officer (CFO) of Pfizer, effective August 15, 2026, ending a four-year tenure during which the drugmaker navigated declining COVID-related revenue and pursued a series of acquisitions.

The company has appointed Cecile Guegan as interim CFO.

Denton is CFO and Executive Vice President (EVP) of Pfizer, and a Member of the company’s Executive Leadership Team. With more than 25 years of finance and operational experience, including over two decades in healthcare, Denton has held senior leadership roles at Pfizer, Lowe’s Companies, and CVS Health. At CVS, he played a key role in the integration of Caremark and the acquisition of Aetna. Earlier, he worked with Deloitte Touche Tohmatsu. Denton holds a business administration degree from Kansas State University and an MBA from Wake Forest University.

Guegan began her career as VP-Finance at AIESEC France before joining PSYGNOSIS as a Business Analyst. Guegan studied at Brest Business School between 1992 and 1995 and has built a career spanning finance leadership and strategic business functions. She is a finance professional with experience across corporate finance, planning, and business analysis.

a

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: